Muscle Loss from GLP-1 Drugs Like Ozempic May Be Less Severe Than Previously Thought
Emerging research indicates that muscle loss associated with GLP-1 drugs like Ozempic may be less significant than previously estimated, with implications for patient safety and long-term use.
New Insights on Muscle Loss with GLP-1 Medications
Recent research suggests that muscle loss associated with GLP-1 receptor agonists such as Ozempic may not be as significant as earlier estimates. While past studies indicated that adults could lose between 5-15% of their body weight with these drugs, a considerable portion of that weight loss was attributed to muscle reduction.
A new study conducted using a mouse model found that muscle loss was around 10%, involving not only skeletal muscles but also other tissues like the liver, which decreased in size by nearly half. This indicates that weight loss from GLP-1 medications may involve complex physiological changes.
Key Findings:
- Muscle loss from GLP-1 drugs may be less than previously believed.
- The reduction affects various tissues, including the liver.
- Muscle strength may decline even if muscle size remains unchanged.
Expert Opinions and Future Directions
Dr. Seth Kipnis emphasizes that some muscle loss is inevitable but stresses the importance of adequate nutrition. Meanwhile, Dr. Kais Rona highlights the need for human trials to better understand these effects, including impacts on muscle function and organ health.
Ongoing research aims to determine whether specific body areas are more vulnerable to muscle loss and how to develop strategies to prevent it, ensuring safer long-term use of GLP-1 medications.
==References==
- Research in Cell Metabolism
- Study in The Lancet
- Expert commentary by Dr. Seth Kipnis
- Interview with Dr. Kais Rona
This evolving research underscores the importance of working with healthcare professionals to monitor muscle health during GLP-1 medication therapy.
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Innovative Lung-on-a-Chip with Immune Function Mimics a Living Organ
A pioneering lung-on-a-chip with an active immune system offers new insights into lung disease, infection response, and personalized therapies, transforming preclinical research and reducing animal testing.
Loss of Smell as an Early Indicator of Increased Mortality and Dementia Risk
A new study links loss of smell in older adults to higher risks of mortality and dementia, emphasizing the importance of olfactory testing in early health assessment.
Understanding the Latest Developments in the COVID-19 Vaccine Policies
Stay informed on the latest updates and controversies surrounding COVID-19 vaccine eligibility and policies in 2025, as states and federal agencies navigate a rapidly changing landscape.
Innovative Algorithm Enhances Vascular Design for 3D Bioprinted Hearts
A new algorithm developed at Stanford significantly speeds up the design of complex vascular networks for 3D bioprinted hearts, paving the way for improved organ manufacturing and regenerative medicine.